Warby Parker Inc. (WRBY), the direct-to-consumer eyewear retailer known for prescription glasses, sunglasses, and contact lenses sold through its stores and e-commerce platform, delivered one of its sharpest single-day rallies in recent memory on Thursday. The stock climbed approximately 24.10%, trading near $26.42 versus a prior-session close of $21.29, marking a gain of more than $5.13 per share. Markets attributed the surge to a combination of solid third-quarter 2026 operating results and the company's announcement that pre-orders for its first Intelligent Eyewear collection will open on November 12, ahead of the holiday shopping season.
The earnings-driven move was anchored by results that showed resilience even in a softer optical retail environment. Warby Parker posted third-quarter revenue of $244.7 million, up 10.4% year over year, roughly in line with analyst expectations. More notably, adjusted EBITDA came in at approximately $28.6 million, exceeding the consensus estimate of about $26.9 million, while GAAP earnings of $0.04 per share topped the $0.03 per share Wall Street had projected. Gross margin improved to 54.4%, and active customers grew 3.0% year over year to 2.74 million.
Management also tightened its outlook, raising the low end of full-year revenue guidance to a range of $966 million to $976 million, which signals roughly 11% to 12% year-over-year growth. The improved guidance reinforced investor confidence that the company's growth initiatives are gaining traction despite softer traffic and pressure on cash-pay consumers across the broader eyewear category.
Beyond the quarterly numbers, the market's enthusiasm centered on the upcoming debut of the company's Intelligent Eyewear collection. Powered by Google's Gemini AI, the smart glasses are designed to deliver voice-activated, context-aware assistance and will be compatible with both Android and Apple's iOS. The product positions Warby Parker to compete directly with Meta's Ray-Ban smart glasses in the fast-growing wearable AI segment.
Investors largely looked past the launch-related costs that pressured quarterly profitability, focusing instead on the category's potential to expand the company's addressable market and attract new customers. With pre-orders opening November 12 and deliveries scheduled during the holiday period, the Intelligent Eyewear rollout is widely seen as a significant catalyst for the crucial fourth quarter.
The rally in WRBY was predominantly idiosyncratic rather than a reflection of broad market strength. Major indices were mixed and largely flat on the day, underscoring that the move was driven by company-specific news. Trading volume ran well above average as investors digested the earnings release and repositioned ahead of the product launch, consistent with a breakout from the stock's recent three-day losing streak. The shares had been heavily sold off in the months leading into the report, leaving the bar relatively low and amplifying the positive reaction to the stronger-than-expected EBITDA and margin performance.
Looking ahead, the market's focus shifts to execution. The November 12 Intelligent Eyewear pre-order window and subsequent holiday-season sales will be closely watched as early indicators of demand for the new category. Investors will also monitor ongoing store expansion, with the company on track for roughly 50 net new openings this year, as well as the growth of its eye exam and care services. Key risks include the execution challenges of scaling a new product category, sustained softness in consumer traffic, and intensifying competition in both traditional eyewear and AI-enabled wearables. Upcoming quarterly results and any updates on Intelligent Eyewear demand will be pivotal in determining whether the rally can be sustained.
Tickeron's Trending AI Robots page highlights a curated selection of the platform's AI-powered trading bots. While Tickeron offers hundreds of bots that monitor thousands of tickers, only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own interests. If you're looking to see which automated strategies are currently leading the market, visit the Trending AI Robots page to learn more.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WRBY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 26, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 46 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WRBY as a result. In 56 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
WRBY moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for WRBY crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
The 50-day moving average for WRBY moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WRBY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where WRBY advanced for three days, in 227 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
WRBY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. WRBY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.714) is normal, around the industry mean (5.069). WRBY's P/E Ratio (354.833) is considerably higher than the industry average of (40.009). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.231) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WRBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther